



PTO/SB/08 (Modified)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/667,289
				Filing Date	09/18/2003
				First Named Inventor	Madaline CHIRICA
				Art Unit	1632-1647
Examiner Name	J. Seharaseyon				
Sheet	1	of	1	Attorney Docket Number	DX01074B

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
JS	AR	US-6,495,667	12-17-2002	BAZAN	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
JS	AS	WO 01/18051 A	03-15-2001	SCHERING CORPORATION		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	10/24/2006
--------------------	---------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not yet known 10/667,289
				Filing Date	Herewith 09/18/2003
				First Named Inventor	Madaline CHIRICA
				Art Unit	Not yet known 1647
				Examiner Name	Not yet known J. Seharaseyon
Sheet	1	of	3	Attorney Docket Number	DX01074B

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code* Number* Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
JS	AA	Kim E. BARRETT, <u>Baillieres Clin. Gastroenterol.</u> , 10(1):1-15, March 1996. "Cytokines: sources, receptors and signalling"	
JS	AB	J. Fernando BAZAN, <i>et al.</i> , <u>Nature</u> , 379:591, February 15, 1996. "A newly defined interleukin-1?"	
JS	AC	J. BRISCOE, <i>et al.</i> , <u>Philos. Trans. R. Soc. Lond. B Biol. Sci.</u> 351(1336):167-71, February 29, 1996. "JAKs, STATs and signal transduction in response to the interferons and other cytokines"	
JS	AD	Irwin M. CHAIKEN & William V. WILLIAMS, <u>Trends Biotechnol.</u> , 14(10):369-75, October 1996. "Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design"	

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	10/23/2006
--------------------	---------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	Not yet known 10/667, 289	
			Filing Date	Herewith 9/18/2003	
			First Named Inventor	Madaline CHIRICA	
			Art Unit	Not yet known 1647	
			Examiner Name	Not yet known J. Seharaseyori	
Sheet	2	of	3	Attorney Docket Number	DX01074B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
JS	AE	THOMAS J. GONDA & RICHARD J. D'ANDREA, <u>Blood</u> , 89(2):355-369, January 15, 1997. "Activating mutations in cytokine receptors: implications for receptor function and role in disease"	
	AF	PETER C. HEINRICH, <i>et al.</i> , <u>Biochem. J.</u> , 334 (Pt 2):297-314, September 1, 1998. "Interleukin 6-type cytokine signalling through the gp130/Jak/STAT pathway"	
	AG	JEFFREY M. HERZ, <i>et al.</i> , <u>J. Recept. Signal Transduct. Res.</u> , 17(5):671-776, September 1997. "Molecular approaches to receptors as targets for drug discovery"	
	AH	M. HIBI, <i>et al.</i> , <u>GenBank</u> , Accession No. M57230, January 6, 1995. Definition: Human membrane glycoprotein gp130 mRNA, complete cds.	
	AI	JAMES N. IHLE, <i>et al.</i> <u>Stem Cells</u> , 15 (Suppl 1):105-11, 1997. "Jaks and Stats in cytokine signaling"	
	AJ	DAVID E. LEVY, <u>Cytokine Growth Factor Rev.</u> , 8(1):81-90, March 1997. "The house that JAK/STAT built"	
	AK	S. LOK, <i>et al.</i> , <u>Database EMBL Online!</u> , Accession Number, AF178684, September 10, 1999. Definition: Homo sapiens class I cytokine receptor (zcytor5) mRNA, complete cds.	
	AL	NEELA PATEL, <i>et al.</i> , <u>J Biol Chem.</u> , 271(48):30386-30391, November 29, 1996. "Functional replacement of cytokine receptor extracellular domains by leucine zippers"	
	AM	DAVID H. PRESKY, <i>et al.</i> , <u>Proc. Natl. Acad. Sci. USA</u> , 93:14002-14007, November 1996. "A functional interleukin 12 receptor complex is composed of two b-type cytokine receptor subunits"	
	AN	D.H. PRESKY, <i>et al.</i> , <u>GenBank</u> , Accession No. U64198, November 28, 2000. Definition: Human IL-12 receptor beta2 mRNA, complete cds.	

Examiner Signature	/Jegatheesan Seharaseyori/	Date Considered	10/23/2006
--------------------	----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 1450, Alexandria, VA 22313-1450.  
 If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

***(Use as many sheets as necessary)***

**C mplete if Kn wn**

Application Number	Not yet known	10/667, 289
--------------------	---------------	-------------

<b>Filing Date</b>	<b>Herewith</b>	<b>9/18/2003</b>
--------------------	-----------------	------------------

First Named Inventor	Madaline CHIRICA
----------------------	------------------

Art Unit	Not yet known	1647
----------	---------------	------

Examiner Name	Not yet known J. Seharaseyon
---------------	------------------------------

Attorney Docket Number DX01074B

Sheet	3	of	3
-------	---	----	---

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2